Commercialization Plan Should Precede Device Development – Big-Cap Firms
This article was originally published in The Gray Sheet
Executive Summary
A well-timed product iteration strategy is central to avoiding price wars with second-comers in various global markets, BD Worldwide Sales & Marketing Director Paul Falkenstein, PhD, suggested Nov. 4
You may also be interested in...
Calif. GPO Bill Gives Small Firms An Alternative To Industry Self-Patrolling
Group purchasing organization administrative fees would be capped at 3% and sole-source contracting for clinical preference items prohibited under legislation circulating in the California Senate
California Safe Needle Law Could Presage Efforts By More States, OSHA
The implementation of legislation in California designed to reduce the incidence of accidental needlesticks among health care workers may prompt additional states to enact laws mandating the use of needles and other sharps designed with protective safety features.
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”